Bosentan Therapy for PAH
- Rationale for ET receptor antagonism
- Preclinical observations
- Clinical pharmacology
- Clinical program:
- Efficacy in patients with PAH
- Overall safety and tolerability
- Specific safety issues
- Drug-induced liver injury (Dr W Maddrey)
- Risk / benefit assessment (Dr L Rubin)